Systematic proteome-wide Mendelian randomization to prioritize causal plasma proteins for skin cancers

Commun Biol. 2024 Dec 19;7(1):1681. doi: 10.1038/s42003-024-07403-y.

Abstract

Skin cancer is one of the most common cancers worldwide. Some risk factors including sun exposure and MC1R variants are recognized; however, the identification of additional genetic factors is essential for the development of novel therapeutic strategies. Here, we conducted a proteome-wide Mendelian randomization (MR) using plasma protein quantitative trait loci (pQTLs) from a published study and the UK Biobank genome-wide association study (GWAS) of skin cancers. We replicated the published result of ASIP, which was significantly associated with increased risks of basal cell carcinoma (BCC) and malignant melanoma. Moreover, we newly identified CTSS, which was significantly associated with a decreased risk of BCC. A series of replication analyses using the DeCODE pQTLs and the FinnGen GWAS, and sensitivity analyses including Steiger filtering, reverse MR, and Bayesian colocalization, supported our primary results. Our findings highlighted the possibility of prioritizing proteins for novel therapeutic or preventive targets and biomarkers for skin cancers.

MeSH terms

  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics
  • Blood Proteins* / genetics
  • Carcinoma, Basal Cell / blood
  • Carcinoma, Basal Cell / genetics
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study*
  • Humans
  • Melanoma / blood
  • Melanoma / genetics
  • Mendelian Randomization Analysis*
  • Polymorphism, Single Nucleotide
  • Proteome*
  • Quantitative Trait Loci*
  • Skin Neoplasms* / blood
  • Skin Neoplasms* / genetics

Substances

  • Proteome
  • Blood Proteins
  • Biomarkers, Tumor